Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Equity Ratio (2016 - 2025)

RedHill Biopharma has reported Equity Ratio over the past 14 years, most recently at 0.17 for Q4 2025.

  • Quarterly Equity Ratio rose 164.88% to 0.17 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.17 through Dec 2025, up 164.88% year-over-year, with the annual reading at 0.17 for FY2025, 164.88% up from the prior year.
  • Equity Ratio was 0.17 for Q4 2025 at RedHill Biopharma, up from 0.24 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.17 in Q4 2025 and troughed at 0.3 in Q4 2022.
  • The 5-year median for Equity Ratio is 0.1 (2021), against an average of 0.08.
  • Year-over-year, Equity Ratio plummeted 721.96% in 2022 and then surged 164.88% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.05 in 2021, then plummeted by 721.96% to 0.3 in 2022, then soared by 129.47% to 0.09 in 2023, then crashed by 389.11% to 0.26 in 2024, then surged by 164.88% to 0.17 in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Equity Ratio are 0.17 (Q4 2025), 0.24 (Q2 2025), and 0.26 (Q4 2024).